Mylan Inc. MYL today
announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a
settlement agreement with Orion Corporation that will resolve patent
litigation related to Entacapone Tablets, 200 mg. Entacapone Tablets are the
generic version of Orion's Comtan^®, indicated as an adjunct to
levodopa/carbidopa therapy to treat patients with idiopathic Parkinson's
Disease who experience the signs and symptoms of end-of-dose "wearing-off".
Under the terms of the settlement agreement, Mylan may launch a generic
version of Comtan, 200 mg, on April 1, 2013, at the earliest. Pursuant to the
agreement, pending litigation will be dismissed. All other terms and
conditions of the settlement are confidential, and the agreement itself is
subject to review by the U.S. Department of Justice and the Federal Trade
Commission.
Entacapone Tablets, 200 mg, had U.S. sales of approximately $104.9 million for
the 12 months ending Sept. 30, 2012, according to IMS Health.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in